Eli Lilly released three-year Phase 3 data for its Crohn's disease treatment, Omvoh (mirikizumab).
The study found that 92.4% of patients who responded to treatment at one year maintained clinical remission through the three-year mark. Corticosteroid-free clinical remission reached 91.2% during the same period. The data also showed that Omvoh significantly reduced disease-related hospitalizations and surgeries.
Omvoh is currently the only IL-23p19 inhibitor to demonstrate this level of durable efficacy over an extended period. These results highlight Eli Lilly’s portfolio diversification beyond its dominant weight-loss drug segment. Eli Lilly shares rose slightly in premarket trading following the announcement.